IMAC vs. OTLK, CUE, GRTS, ASRT, ALLK, FONR, CTXR, BLUE, KRMD, and GNLX
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Outlook Therapeutics (OTLK), Cue Biopharma (CUE), Gritstone bio (GRTS), Assertio (ASRT), Allakos (ALLK), FONAR (FONR), Citius Pharmaceuticals (CTXR), bluebird bio (BLUE), KORU Medical Systems (KRMD), and Genelux (GNLX). These companies are all part of the "medical" sector.
IMAC (NASDAQ:IMAC) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.
IMAC has higher revenue and earnings than Outlook Therapeutics.
Outlook Therapeutics has a consensus price target of $46.43, suggesting a potential upside of 496.72%. Given Outlook Therapeutics' higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than IMAC.
Outlook Therapeutics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Outlook Therapeutics' return on equity.
24.3% of IMAC shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Comparatively, 5.3% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Outlook Therapeutics had 8 more articles in the media than IMAC. MarketBeat recorded 9 mentions for Outlook Therapeutics and 1 mentions for IMAC. IMAC's average media sentiment score of 0.33 beat Outlook Therapeutics' score of -0.05 indicating that IMAC is being referred to more favorably in the media.
Outlook Therapeutics received 84 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 70.45% of users gave Outlook Therapeutics an outperform vote while only 60.17% of users gave IMAC an outperform vote.
IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
Summary
IMAC and Outlook Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
